Current and future use of remdesivir in patients with COVID-19
There are prerequisites for the use of remdesivir against SARS-CoV-2 in stationary conditions. Remdesivir is not registered in the Russian Federation. The preliminary results of randomized clinical trials on the efficacy of remission are contradictory.
Saved in:
Main Authors: | V. M. Tsvetov (Author), K. B. Mirzaev (Author), D. A. Sychev (Author) |
---|---|
Format: | Book |
Published: |
Izdatelstvo OKI,
2020-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current and future use of dipyridamole in patients with COVID-19
by: I. S. Burashnikova, et al.
Published: (2020) -
Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy
by: V. M. Tsvetov, et al.
Published: (2020) -
Current and future use of umifenovir in patients with COVID-19
by: Yu. Yu. Kiselev, et al.
Published: (2020) -
Is it possible to use riamilovir to prevent infection and treat COVID-19?
by: V. M. Tsvetov, et al.
Published: (2020) -
Current and future use of colchicine in patients with COVID-19
by: Yu. Yu. Kiselev, et al.
Published: (2020)